VC-Backed Biotech IPOs Expected to Flex Their Muscle Through Early Fall

Fenwick’s capital markets & public companies practice co-chair Rob Freedman spoke with Venture Capital Journal about the current state of biotech IPOs and how the COVID-19 pandemic may have affected investment in the space.

“I am hearing that there will be a lot of biotech companies coming out over the summer,” Freedman said. “July and August are going to be very busy. Despite what is going on with COVID-19, these companies are seeing interest from public markets as long as there is strong management and compelling technology in place.”

Freedman told Venture Capital Journal that several factors have generated interest from investors. For example, many biotech companies are viewed as long-term investments as their IPOs are pre-revenue with sometimes 6-10 years before a product hits the market. The COVID-19 pandemic has also highlighted the increased importance of these companies in the life sciences sector, Freedman noted.

The full article is available on Venture Capital Journal (subscription required).


Don’t have an account yet?